| Drug NDC: | 71233-002 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Weight Management |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Asclepias Vinc, Echinacea, Hypothalamus, Cerebrum Suis, Hepar Suis, Kidney, Methylcobalamin, Pancreas Suis, Stomach Suis, Aacg-a, Aacg-b, Calc Carb, Gambogia, Gelsemium, Graphites, Nat Mur, Nux Vom, Phytolacca, 3-acetyl-7-oxo-dehydroepiandrosterone, Atp, Glucagon, Insulinum, Sarcolacticum Ac, Proteus |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Compass Fat Loss Of Glastonbury Llc |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | 7-KETO-DEHYDROEPIANDROSTERONE - 30 [hp_X]/59mL ADENOSINE TRIPHOSPHATE DISODIUM - 30 [hp_X]/59mL APC-356433 - 8 [hp_X]/59mL APC-356434 - 8 [hp_X]/59mL BOS TAURUS HYPOTHALAMUS - 6 [hp_X]/59mL CYNANCHUM VINCETOXICUM ROOT - 6 [hp_X]/59mL ECHINACEA, UNSPECIFIED - 6 [hp_X]/59mL GAMBOGE - 12 [hp_X]/59mL GELSEMIUM SEMPERVIRENS ROOT - 12 [hp_X]/59mL GLUCAGON - 30 [hp_X]/59mL Load more... GRAPHITE - 12 [hp_X]/59mL INSULIN PORK - 30 [hp_X]/59mL LACTIC ACID, L- - 30 [hp_X]/59mL METHYLCOBALAMIN - 8 [hp_X]/59mL OYSTER SHELL CALCIUM CARBONATE, CRUDE - 12 [hp_X]/59mL PHYTOLACCA AMERICANA ROOT - 12 [hp_X]/59mL PORK KIDNEY - 8 [hp_X]/59mL PORK LIVER - 8 [hp_X]/59mL PROTEUS VULGARIS - 30 [hp_C]/59mL SODIUM CHLORIDE - 12 [hp_X]/59mL STRYCHNOS NUX-VOMICA SEED - 12 [hp_X]/59mL SUS SCROFA CEREBRUM - 8 [hp_X]/59mL SUS SCROFA PANCREAS - 8 [hp_X]/59mL SUS SCROFA STOMACH - 8 [hp_X]/59mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 03 Apr, 2017 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 19 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Compass Fat Loss of Glastonbury LLC |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000190852 N0000190853 N0000009340 N0000009345 N0000008636 N0000008635 N0000008652 N0000185375 N0000175629 N0000184306 N0000185001 M0000728 M0016962 M0516536 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | 2334LJD2E9 5L51B4DR1G TX3FV9N212 NN413ZO15B S6G2NLH4Y7 9R858U917W 4N9P6CC1DX 7556HJ7587 639KR60Q1Q 76LA80IG2G Load more... 4QQN74LH4O AVT680JB39 F9S9FFU82N BR1SN1JS2W 2E32821G6I 11E6VI8VEG X7BCI5P86H 6EC706HI7F 11T9HCO30O 451W47IQ8X 269XH13919 4GB5DQR532 9Y3J3362RY T0920P9Z9A |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class EPC: | Antihypoglycemic Agent [EPC] Gastrointestinal Motility Inhibitor [EPC] Non-Standardized Plant Allergenic Extract [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Gluconeogenesis [PE] Increased Glycogenolysis [PE] Decreased GI Smooth Muscle Tone [PE] Decreased GI Motility [PE] Decreased Glycolysis [PE] Increased Histamine Release [PE] Cell-mediated Immunity [PE] Increased IgG Production [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Allergens [CS] Plant Proteins [CS] Seed Storage Proteins [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Antihypoglycemic Agent [EPC] Cell-mediated Immunity [PE] Decreased GI Motility [PE] Decreased GI Smooth Muscle Tone [PE] Decreased Glycolysis [PE] Gastrointestinal Motility Inhibitor [EPC] Increased Gluconeogenesis [PE] Increased Glycogenolysis [PE] Increased Histamine Release [PE] Increased IgG Production [PE] Increased Large Intestinal Motility [PE] Inhibition Large Intestine Fluid/Electrolyte Absorption [PE] Non-Standardized Plant Allergenic Extract [EPC] Osmotic Activity [MoA] Osmotic Laxative [EPC] Plant Proteins [CS] Seed Storage Proteins [CS] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 71233-002-02 | 59 mL in 1 BOTTLE, DROPPER (71233-002-02) | 03 Apr, 2017 | N/A | No |
| 71233-002-07 | 74 mL in 1 BOTTLE, DROPPER (71233-002-07) | 03 Apr, 2017 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.